ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors

ONA Therapeutics Appoints Dr Michel…

Confo Therapeutics Enters Collaborative Agreement with Regeneron

Confo Therapeutics Enters Collaborative Agreement…

Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis

NEW YORK, Nov. 18, 2021…

Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activity

– Fully Enrolled Phase 2…

Additional data from Minoryx’s Phase 2/3 ADVANCE clinical trial presented at American Neurological Association (ANA) 2021

Presentation highlights reduction in cerebral…

Novadip Biosciences announces EUR 19 million Series B financing backed by international investors

Novadip Biosciences announces EUR 19…

Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis

  – Top-Line Data Expected…